Abstract
Social phobia is a prevalent and debilitating psychiatric disorder. It entails significant economic costs in the form of educational underachievement, increased financial dependency, decreased work productivity, social impairment and poorer quality of life. It is associated with increased prevalence of other psychiatric disorders including depression and alcohol dependence. Its onset is early and typically precedes onset of comorbid disorders. Despite its debilitating effects, social phobia is often unrecognised and is undertreated. The availability of efficacious pharmacological and psychotherapeutic treatments for social phobia makes it imperative to carefully consider the impact of this disorder and to consider the cost effectiveness of available treatments.
Similar content being viewed by others
References
American Psychiatric Association. Diagnostic Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
Stein MB. How shy is too shy? Lancet 1996; 347: 1131–2
Weissman MM, Bland RC, Caninio GJ, et al. The cross-national epidemiology of social phobia: a preliminary report. Int Clin Psychopharmacol 1996; 11 (3): 9–14
Schneier FR, Johnson J, Hornig CD, et al. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992; 49: 282–8
Davidson JRT, Hughes DC, George LK, et al. The boundary of social phobia: exploring the threshold. Arch Gen Psychiatry 1994; 51: 975–83
Magee WJ, Eaton WW, Wittchen HU, et al. Agoraphobia, simple phobia, and social phobia in the national comorbidity survey. Arch Gen Psychiatry 1996; 53: 159–68
Stein MB, Walker JR, Forde DR. Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. Am J Psychiatry 1994; 151: 408–12
Wittchen HU, Stein MB, Kessler RC. Social fears and social phobia in a community sample of adolescents and young adults: prevalence, risk factors, and comorbidity. Psychol Med 1999; 29: 309–23
Wacker HR, Mullejans R, Klein KH, et al. Identification of cases of anxiety disorders and affective disorders in the community according to ICD-10 and DSM-III-R using the Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 1992; 2: 91–100
Weiller E, Bisserbe JC, Boyer P, et al. Social phobia in general health care: an unrecognized undertreated disabling disorder. Br J Psychiatry 1996; 168: 169–74
Katzelnick DJ, Kobak KA, Helstad CP. The direct and indirect costs of social phobia in managed care patients. Paper presented at the 37th Annual Meeting of the Neuropsychopharmacology; 1998 Dec 14–18; Los Croabas
Heimberg RG, Juster HR. Cognitive behavioral treatments: literature review. In: Heimberg RG, Liebowitz MR, Hope DA, et al., editors. Social phobia: diagnosis, assessment and treatment. New York (NY): Guilford, 1995: 261–309
Ost LG. Age of onset in different phobias. J Abnorm Psychol 1987; 96: 223–9
Reich J, Goldenberg I, Vasile R, et al. A propective follow-along study of the course of social phobia. Psychiatry Res 1994; 54: 249–58
McGee R, Freehan M, Williams S, et al. DSM-III disorders in a large sample of adolescents. J Am Acad Child Adolesc Psychiatry 1990; 29: 611–9
Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo controlled comparison. Arch Gen Psychiatry 1992; 49: 290–300
Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia: a randomized controlled trial. JAMA 1998; 280: 708–13
Prince MJ, Harwood RH, Blizard RA, et al. Social support deficits, loneliness and life events as risk factors for depression in old age. The Gospel Oak Project VI. Psychol Med 1997; 27: 323–32
Stein MB, Walker JR, Forde DR. Public speaking fears in a community sample: prevalence, impact on functioning, and diagnostic classification. Arch Gen Psychiatry 1996; 53: 169–74
Kessler RC, Stein MB, Berglund P. Social phobia subtypes in the national comorbidity survey. Am J Psychiatry 1998; 155: 613–9
Gelernter CS, Stein MB, Tancer ME, et al. An examination of syndromal validity and and diagnostic subtypes in social phobia and panic disorder. J Clin Psychiatry 1992; 53: 23–7
Mannuzza S, Schneier FR, Chapman TF. Generalized social phobia: reliability and validity. Arch Gen Psychiatry 1995; 52: 230–7
Turner SM, Beidel DC, Dancu CV, et al. Psychopathology of social phobia and comparison to avoidant personality disorder. J Abnorm Psychol 1986; 95: 389–94
Sanderson WC, Dinardo PA, Rapee RM, et al. Syndrome comorbidity in patients diagnosed with DSM-III-R anxiety disorder. J Abnorm Psychol 1990; 99: 308–12
Van Ameringen, Mancini C, Styan G, et al. Relationship of social phobia with other psychiatric illness. J Affect Dis 1991; 21: 93–9
Schuckit MA, Hesselbrock V. Alcohol dependence and anxiety disorders: what is the relationship? Am J Psychiatry 1994; 151: 1723–34
Bulik CM, Beidel DC, Duchmann E, et al. An analysis of social anxiety in anorexic, bulimic, social phobic, and control women. J Psychopathol Behav Assoc 1991; 13: 199–211
Angst J. Comorbidity of anxiety, compulsions, and depression. Int Clin Psychopharmacol 1993; 8: 21–5
Van Vliet IM, der Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia: a double blind placebocontrolled study with fluvoxamine. Psychopharmacology 1994; 115: 128–34
Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind placebo-controlled, crossover study. Am J Psychiatry 1995; 152: 1368–71
Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993; 13: 423–8
Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo controlled study. J Clin Psychopharmacol 1999; 19: 341–8
Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12 week outcome. Arch Gen Psychiatry 1998; 55: 1133–41
Wells KB, Stewart A, Hays RD. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989; 262: 914–9
Markowitz JS, Weissman MM, Oulette R, et al. Quality of life in panic disorder. Arch Gen Psychiatry 1989; 46: 984–92
Roy-Byrne PP, Stein MB, Russo J, et al. Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment. J Clin Psychiatry 1999; 60: 492–9
Davidson JRT, Hughes DL, George LK, et al. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol Med 1993; 23: 709–18
Last CG, Strauss CC. School refusal in anxiety diosordered children and adolescents. J Am Acad Child Adolesc Psychiatry 1990; 29: 31–5
Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999; 60: 427–35
Schneier FR, Heckelman LR, Garfinkel R, et al. Functional impairment in social phobia. J Clin Psychiatry 1994; 55: 322–31
Wittchen HU, Beloch E. The impact of social phobia on quality of life. Int Clin Psychochopharmacol 1996; 11 (3): 15–23
Lecrubier Y. Comorbidity in social anxiety disorder: impact on disease burden and management. J Clin Psychiatry 1998; 59 (17): 33–7
Norton GR, McLeod L, Guertin J, et al. Panic disorder or social phobia: which is worse? Behav Res Ther 1996; 34: 273–6
Lepine JP, Lellouch J. Diagnosis and epidemiology of agoraphobia and social phobia. Clin Neuropharmacol 1995; 18 (2): 15–26
Ballenger JC, Burrows GD, Dupont RL, et al. Alprazolam in panic disorder and agoraphobia: results from a multi-center trial I: efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45: 413–22
Safren SA, Heimberg RG, Brown EJ. Quality of life in social phobia. Anxiety 1997: 4: 126–33
Bech P, Angst J. Quality of life in anxiety and social phobia. Int Clin Psychochopharmacol 1996; 11 (3): 97–100
Antony MM, Roth D, Swinson RP, et al. Illness intrusiveness in individuals with panic disorder, obsessive-compulsive disorder, or social phobia. J Nerv Ment Dis 1998; 186: 311–5
Rice DP, Kelman S, Miller LS. The economic burden of mental illness. Hosp Comm Psychol 1992; 43: 1227–32
DuPont RL, Rice DP, Miller LS. Economic costs of anxiety disorders. Anxiety 1996; 2: 167–72
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lipsitz, J.D., Schneier, F.R. Social Phobia. Pharmacoeconomics 18, 23–32 (2000). https://doi.org/10.2165/00019053-200018010-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200018010-00003